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Introduction: Guided migration of chondrogenically differentiated cells has not been well studied, even though it
may be critical for growth, repair, and regenerative processes. The chemokine CCL25 is believed to play a critical
role in the directional migration of leukocytes and stem cells. To investigate the motility effect of serum- or
CCL25-mediated chemotaxis on chondrogenically differentiated cells, mesenchymal stem cells (MSCs) were induced
to chondrogenic lineage cells.
Methods: MSC-derived chondrogenically differentiated cells were characterized for morphology, histology,
immunohistochemistry, quantitative polymerase chain reaction (qPCR), surface profile, and serum- or
CCL25-mediated cell migration. Additionally, the chemokine receptor, CCR9, was examined in different states
of MSCs.
Results: The chondrogenic differentiated state of MSCs was positive for collagen type II and Alcian blue staining,
and showed significantly upregulated expression of COL2A1and SOX9, and downregulated expression of CD44,
CD73, CD90, CD105 and CD166, in contrast to the undifferentiated and dedifferentiated states of MSCs. For the
chondrogenic differentiated, undifferentiated, and dedifferentiated states of MSCs, the serum-mediated chemotaxis
was in a percentage ratio of 33%:84%:85%, and CCL25-mediated chemotaxis was in percentage ratio of
12%:14%:13%, respectively. On the protein level, CCR9, receptor of CCL25, was expressed in the form of extracellular
and intracellular domains. On the gene level, qPCR confirmed the expression of CCR9 in different states of MSCs.
Conclusions: CCL25 is an effective cue to guide migration in a directional way. In CCL25-mediated chemotaxis,
the cell-migration rate was almost the same for different states of MSCs. In serum-mediated chemotaxis, the
cell-migration rate of chondrogenically differentiated cells was significantly lower than that in undifferentiated or
dedifferentiated cells. Current knowledge of the surface CD profile and cell migration could be beneficial for
regenerative cellular therapies.
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Human mesenchymal stem cells (MSCs) hold great
promise for tissue regeneration. During tissue repair,
MSCs migrate to the sites of injury and participate in
the repair process [1,2]. Stem cell migration not only
plays a potential role in cell colonization inside bioma-
terial scaffolding [3], but also takes part in the reor-
ganization of matrix [4]. Moreover, the guided migration
of MSCs creates a therapeutic environment for bone re-
generation [5]. These features emphasize the importance
of targeted stem cell migration in tissue-engineering
approaches.
Stem cell migration improves the curative ability of
diseased tissues via appropriate homing inside injured
sites [1,2,6]. Previously, it was reported that cell migra-
tion and subsequent suitable colonization of progenitor
stem cells within injured sites accelerate myocardial re-
generation [7,8], reduce heart damage [9,10], aid in re-
covery from spinal-cord injuries [11], cure nerve damage
[12], and repair cartilage [13,14]. The MSCs have the
potential to migrate through bone marrow endothelium,
by using the regulatory mediators of matrix metal-
loproteinase-2 and tissue-inhibitor metalloproteinase-3
[15]. The administration of allogenic MSCs, whether de-
rived from bone marrow or from adipose tissue, was
reported for cellular proliferation, neurogenesis, and
takes part in the functional recovery of brain after ische-
mic stroke [16]. Moreover, clinical trials of using human
MSCs for bone fractures, bone defects, and cartilage dis-
orders have been performed [17-19]. The investigation
of targeted stem cell migration could be beneficial for
tissue regeneration, especially for cartilage restoration.
Chondrocytes in the articular cartilage lack innervations
and vascularization and have low mitotic potential.
Moreover, the chondrocytes have no physical contact to
each other and entrapped into extracellular matrix
[20-22]. These features make cartilage restoration is a
hot issue in case of regeneration.
Autologous chondrocyte transplantation is an es-
tablished technique for cartilage repair [23-25], which
consists of chondrocyte isolation, in vitro dedifferenti-
ation, and transplantation [25-27]. It is established
that dedifferentiation is necessary to achieve a high
cell number, and it is considered a curative step in
such technologies [28-30]. However, massive dediffer-
entiation of chondrocytes results in loss of the
chondrogenic phenotype and formation of primitive
multipotent cell types [28-31]. To overcome such
shortcomings, chondrogenic maintenance cues such
as cytokines, chemokines, and growth factors are re-
quired to regulate and control the process of chon-
drocyte transplantation. The theoretic assumption is
that this would increase remedial time and thera-
peutic cost because of in vivo posttransplantationalprocedures for chondrogenic differentiation and main-
tenance. It necessitates the use of such culture tech-
niques and cell types, which not only maintain a
chondrogenic-specific phenotype, from the beginning
of transplantation, but also proliferate to increase the
number of cells.
Therefore, the direct mobilization of endogenous cells
and subsequent migration to the point of injury could be
a promising approach for cartilage regeneration. In this
context, the motility and migratory features of chon-
drocytes have been characterized [32]. To investigate the
migratory effect of serum- or CCL25-mediated chemo-
taxis on chondrogenic cells, we isolated differentiated
cells from compact pellets, after 28 days of chondrogenic
differentiation. They maintained the chondrogenic na-
ture for about 14 days in the culture and were able to
proliferate. After chondrogenic confirmation, their sur-
face profile and cell-migration ability were examined for
serum- or CCL25-mediated chemotaxis.
Present strategies of stem cells transplantation advo-
cate the use of MSCs [23,33-35], for diverse regenerative
application, including cartilage repair [23,26]. In some
cases, the clinical use of MSCs is considered more
valuable than autologous chondrocytes transplantation
[36,37], as it requires one less knee surgery, is easy to
isolate, has a high proliferative rate, reduces cost, and
provides better regenerative efficiency [28,35,36]. For in-
stance, the use of magnetized MSCs is the best choice
for articular cartilage repair [38]. In such cases, one con-
troversial and basic question needs an answer: which cell
type would be more suitable for cartilage regeneration,
undifferentiated MSCs or their chondrogenic differen-
tiated progeny? Therefore, we investigated the cell-
migration profile of chondrogenically differentiated cells
compared with the undifferentiated and dedifferentiated
states of MSCs, according to already described formula-
tion and concentration of allogenic serum [39].
However, allogenic serum has a complex composition
[40-42], which is unknown and undefined for some mo-
lecular functions. It emphasizes the need for a defined
and targeted chemokine, to make the present regenera-
tive strategies more valuable and beneficial for appropri-
ate cell homing. Moreover, chemokines are recognized
as an essential factors for diverse cellular process includ-
ing activation of the central hub of cellular migration via
direct or indirect mechanisms and signaling events
[39,43-45], and stimulation of the therapeutic efficiency
of regeneration.
Chemotaxis is defined as directional movement of cells
toward concentration gradients or chemoattractants,
whereas chemokinesis is random cell movement without
any chemoattractants [46]. Directional migration of
MSCs to the site of injury is controlled by several
factors, such as hypoxia and the Rho family of GTPases
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dinating and well-regulating cell migration for its restor-
ation in response to different cues like cytokines and
growth factors [43,49]. Apart from this, chemokines play
a vital role in a biologic plethora of migration and are
considered guided cues for directional and targeted stem
cell trafficking [39,43,49]. Chemokines enable the activity
of migratory processes in hematopoietic and nonhe-
matopoietic cells [50], navigate the cellular trafficking
between tissue compartments, and play a potential role
in cell activation, differentiation, survival, and recruit-
ment of leukocytes [51]. In addition, they play a decisive
role in mobilization of T lymphocytes during allergenic
reactions [52] and contribute to the complex patho-
physiology of asthma by using the coordinating network
of cellular activation and signaling web [53].
Chemokine-based recruitment of MSCs to the point
of injury is a promising approach, whereas chemokine
(C-C motif ) ligand 25 (CCL25) could play a vital role in
cell migration [44,54]. After nerve damage or myocardial
infarction, the mutual interactions of chemokines and
their receptors mediate the migration of MSCs to in-
jured sites [55]. Obviously, to understand the underlying
mechanism would be of interest. In this context, CCL25
has been suggested as a potential chemoattractant for
the directional movement of MSCs [56], and C-C che-
mokine receptor type 9 (CCR9) is known as a cognate
receptor of CCL25 [57,58]. To check whether the
chondrogenic differentiated state of MSCs affects the
cell-migration rate, we performed the chemotaxis assay
for undifferentiated, chondrogenic differentiated and
dedifferentiated cells, by using the chemokine CCL25
[54]. Furthermore, the receptor CCR9 was examined in
different states of MSCs, as CCR9 is an established
known receptor of CCL25 and plays a decisive role in
the targeted migration of stem cells [43,44,54].
To cope with the challenges of the growing tissue-
engineering industry, we need an appropriate cell source
and suitable cell types, which are able not only to mi-
grate to the site of injuries or damage in a well-guided
way, but also to facilitate quick regeneration. Our intro-
duced cell types could be valuable and beneficial in this
regard.
Materials and methods
Ethics statement and MSC isolation
The study was approved by the institutional ethical com-
mittee of the Charité-University Medicine Berlin. Writ-
ten informed consent was obtained from all participants,
as a requirement of the ethical review board. The human
MSCs were isolated from iliac crest bone marrow aspi-
rates (n = 3; two men, one women; average age, 52.3 ±
1.5 years) of the healthy donors, who were examined to
exclude hematopoietic neoplasms and were histologicallydiagnosed as normal. The 1-ml aspirate was seeded per
T175 cm2 of culture flasks (Becton Dickinson, Heidelberg,
Germany). After 72 hours, nonadherent cells and cellular
debris were washed out by media exchange, and cultures
were further expanded in Dulbecco Modified Eagle
Medium (DMEM; Biochrom, Berlin, Germany), supple-
mented with 10% fetal bovine serum (FBS; Hyclone,
Cramlington, UK), 20 mM Hepes buffer (Biochrom), 2
mM L-glutamine (Biochrom), 2 ng/ml human basic-
fibroblast growth factor (bFGF; Pepro Tech, London, UK)
100 units/ml penicillin and 100 μg/ml streptomycin
(Biochrom), under established conditions. After expansion
and subsequent confluences, the cells were detached with
trypsin (0.05% 1 mM EDTA), and replated until passage 3.
Chondrogenic differentiation
For chondrogenic differentiation, 2.5 × 105 MSCs were
centrifuged (150 g, 5 minutes) to form high-density
micromass culture pellets. The chondrogenic differenti-
ation of these pellets was achieved for 28 days with
DMEM (4.5 g/L glucose; Biochrom), ITS supplements,
100 nM dexamethasone, 0.17 mM ascorbic acid-2-phos-
phate, 1 mM sodium pyruvate, 0.35 mM L-proline (all
Sigma-Aldrich) and 10 ng/ml transforming growth
factor-β3 (TGF-β3; PeproTeck, Hamburg, Germany).
The control pellets were cultured in the same medium
in the absence of TGF-β3. The medium (500 μl) was
changed 3 times per week.
Cell isolation from chondrogenic pellets and
dedifferentiation
After chondrogenic differentiation of the pellets for 28
days, cells were isolated with 300 U of collagenase II,
20 U of collagenase P, and 2 mM CaCl2 for 90 minutes
at 37°C [59]. Subsequently, some cells were cultured in a
monolayer for 14 days in the presence of the chon-
drogenic differentiation-specific stimulus of TGF-β3, to
maintain their chondrogenic nature. Conversely, the
chondrogenically differentiated cells were cultured for
five passages in the normal MSC expansion medium to
accelerate proliferation and to generate dedifferentiated
progenitor cells.
Flow-cytometric analysis for cell-surface screening
Fluorescence-activated cell sorting (FACS) analysis was
performed not only to characterize the MSCs for their
typical specific surface antigens, but also to determine
the expression of these antigens in chondrogenic differ-
entiated and dedifferentiated cells. For all experimental
cell types, the cells (n = 3) were prepared in the form of
a single-cell suspension, then washed with PBS/0.5% bo-
vine serum albumin (BSA; both Biochrom), and cen-
trifuged for 5 minutes at 250 g. The resuspended cells in
the cold PBS/0.5% BSA were incubated for 15 minutes
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CD14, CD34, CD73, CD166, and fluorescein isothiocyanate
(FITC)-labeled mouse anti-human CD44, CD45, CD90, and
CD105 antibodies. All antibodies were purchased from BD-
Pharmingen (Heidelberg, Germany) except CD105, which
was purchased from Acris Antibodies (Hiddenhausen,
Germany).
After incubation, the cells were centrifuged (250 g, 5
minutes), washed with cold PBS/0.5% BSA, and re-
suspended in the same buffer before cytometric analysis.
To examine the extracellular domain of CCR9 receptor,
staining was performed as described earlier but with
PE-labeled mouse anti-human CCR9 (R&D Systems,
Wiesbaden, Germany). For measurement of the intracel-
lular domain of the CCR9 receptor, one additional step
of permeabilization was added. After fixation with 4%
paraformaldehyde (Sigma, Germany) for 15 minutes,
cells were permeabilized for 10 minutes with FACS per-
meabilizing solution-2 (Becton Dickinson, Germany)
and then processed as described earlier. The propidium
iodide (100 μg/ml; Sigma-Aldrich) staining was applied
for the exclusion of dead cells and cellular debris,
whereas unstained cells were used as a negative control.
The single-cell suspension was analyzed with flow cy-
tometry, and CellQuest software (Becton Dickinson) was
used for the interpretation and analysis of results.
Migration potential of cells
Migration potential of MSCs, chondrogenic differentiated
cells, and dedifferentiated cells were assessed in response
to 10% human allogenic serum or CCL25 chemokine
(PeproTech, Germany). An already established chemotaxis
assay by our group [33,54,60], was performed for all cell
types with 8-μm pore size polycarbonate membranes in
96-multiwell format ChemoTx plates (Neuroprobe,
Gaithersburg, USA). For migration of cells, either 10%
allogenic serum or a selected concentration of CCL25
(500 nm, 750 nm, and 1,000 nm) [54] was applied in tripli-
cate to the lower wells. The 4 × 104 cells for serum and
3 × 104 cells for CCL25 were seeded in the upper wells
and incubated for 20 hours at 37°C. Negative controls
were performed without chemokine or serum. Migrated
cells were fixed in methanol/acetone, stained with
hemacolor (Merck, Germany), and counted microscopic-
ally with Image J software.
Histology and immunohistochemistry
To examine chondrogenesis, the high-density micromass
pellets were embedded in Tissue-Tek with O.C.T com-
pound (Sakura Finetek, Torrance, USA), and then were
frozen in liquid nitrogen and cryosectioned (6-μm thick-
ness). For the cartilage-specific proteoglycan examination,
these sections were stained with Alcian blue 8GX (Roth,
Karlsruhe, Germany) and counterstained with nuclear fastred (Sigma Aldrich). For the deposition and accumulation
of collagen type II in the ECM, cryosections (6 μm) were
incubated for 1 hour with primary rabbit anti-human type
II collagen antibodies (Acris Antibodies). Subsequently, the
sections were processed according to the manufacturer’s
recommendation with the Envision system peroxidase kit
(DAKO, Hamburg, Germany), followed by hematoxylin
counterstaining (Merck, Darmstadt, Germany). The
stained sections in the control samples were prepared
from the chondrogenic control pellets.
To stain the chondrogenic differentiated and dedif-
ferentiated cells, 2 × 105 cells were transferred to each well
of the four-well chamber slides (Thermo-scientific,
Germany). The cells inside chamber slides were cultured
for 3 days under standard conditions to ensure the proper
attachment of the cells to the slide surface. For direct
staining, the cells were fixed for 5 minutes in already
cooled 3.7% formaldehyde in PBS. Subsequently, cells
were stained according to the standard procedure, as
described for cryosections of the chondrogenic pellets.RNA isolation and qPCR
For RNA isolation, the MSCs, chondrogenic differentiated,
and dedifferentiated cells were mixed with TriReagent
(Sigma-Aldrich). While the differentiated chondrogenic
pellets [11-17], were first pooled for each individual donor
(n = 3) in the 2-ml Eppendorf tube, then the TriReagent
was mixed with these pellets and mechanically homoge-
nized with an Ultra-Turrax (IKA, Staufen, Germany).
Then 1-bromo-3-chloro-propane (Sigma-Aldrich) was
added to all samples, followed by centrifugation (45 mi-
nutes, 13,000 g), and the upper phase, being free of pro-
teins, was collected and mixed with an equal amount of
ethanol. Subsequently, samples were processed with the
RNeasy Mini Kit (Qiagen, Hilden, Germany), according to
manufacturer recommendation. The quantity and quality
of eluted RNA was ensured with NanoDrop measure-
ments (NanoDrop Products, Wilmington, USA).
For qPCR, cDNA was synthesized from 2.5 μg total RNA
by using the iScript cDNA synthesis kit (BioRad, Munich,
Germany). The TaqMan qPCR was executed in triplicates
in 96-well optical plates on a Mastercycler ep Realplex2 S
system (Eppendorf, Hamburg, Germany). The gene-
expression assays for typical chondrogenic-specific genes
was performed with TaqMan probes and primer sets
(Applied Biosystems, Darmstadt, Germany). Quantitative
gene expression was analyzed for collagen type 2 A1
(COL2A1; Hs 00264051_m1), SRY (sex-determining re-
gion Y)-box-9 (SOX9; Hs 00165814_m1), C-C chemokine
receptor type 9 (CCR9; Hs 01890924_s1), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
Hs99999905_m1). The expression of COL2A1 and SOX9
genes was normalized to the endogenous GAPDH
Figure 1 (See legend on next page.)
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Figure 1 MSC isolation, confirmation, and chondrogenic differentiation. (A) MSCs appeared as single cells in P0, and (B) showed uniform
growth and fibroblast-like morphology in P3. (C) Flow-cytometric analysis revealed positive expression for typical MSC antigens like CD166,
CD105, CD90, CD73, and CD44, but negative expression for hematopoietic lineage-specific antigens like CD45, CD34, and CD14 (three biologic
replicates; n = 3), mean ± SEM. (D) On chondrogenic differentiation, they showed positive expression for Alcian blue staining compared with
(E) control. (F) Similarly, they were positive for collagen type II expression compared with (G) unstimulated samples. (H) On the gene level, the
chondrogenic differentiation was confirmed by significantly upregulated expression of COL2A1 and SOX9 genes compared with negative controls
and undifferentiated MSCs, day 0 (n = 3). Student t test was performed for statistical analysis, and asterisks were assigned in the order P* < 0.05,
P** < 0.01, and P*** < 0.001; mean ± SEM. Bar A, B, 500 μm; D through G, 200 μm.
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in percentage of GAPDH expression [61].
Statistical analysis
The statistical analysis was performed by using SigmaStat
3.5 software (Systat Software, USA), whereas GraphPad
Prism4 (GraphPad Software) was used for drawing graphs.
Simple Student t test was used for statistical assessment,
and asterisks were assigned in the order P* < 0.05, P** <
0.01, and P*** < 0.001 for statistically significant values,
whereas exact P values were mentioned for statistically
nonsignificant data sets. Error bars in all figures represent
standard error of the mean.
Results
MSC isolation, authentication, and chondrogenic
differentiation
Human MSCs were isolated from bone marrow aspi-
rates, as shown in the form of individual longitudinal
cells in P0 (Figure 1A), which became homogeneous
with subsequent growth and revealed the typical
fibroblast-like morphology in P3 (Figure 1B). The sur-
face screening of MSCs showed a positive expression for
CD44, CD73, CD90, CD105, and CD166, and a nega-
tive expression for CD14, CD34, and CD45 antigens
(Figure 1C). For MSCs, the FACS histogram plots are
shown in supplementary Figure 1 (see Additional file 1:
Figure S1), and their adipogenic, osteogenic, and chon-
drogenic potential was shown elsewhere [62]. The
comparative flow-cytometric analysis of MSCs showed
higher expression for their surface antigens compared
with chondrogenic cells, as shown as a mean of three
donors (see Additional file 2: Figure S5). Characterized
MSCs were then induced to chondrogenic lineage differ-
entiation. After 28 days of chondrogenic stimulation, the
6-μm-thick cryosections of the pellets showed cartilage-
specific proteoglycan and were positive for Alcian blue
staining (Figure 1D), in contrast to unstimulated control
samples (Figure 1E). The chondrogenic ability of these
samples was further ensured by the positive expression
of cartilage-specific collagen type II (Figure 1F), com-
pared with control samples (Figure 1G). On the gene
level, the chondrogenic nature was verified by the ex-
pression of cartilage-specific genes COL2A1 and SOX9.Both genes showed significantly upregulated expression
in the chondrogenic samples compared with undiffe-
rentiated MSCs and controls (Figure 1H). These re-
sults confirmed the well-advanced state of chondrogenic
differentiation.
Isolation of chondrogenic differentiated cells
After 28 days of chondrogenic differentiation, the cells
were isolated from the compact pellets with enzymatic
cues consisting of 300 U of collagenase II, 20 U of colla-
genase P, and 2 mM CaCl2 (Figure 2) [59]. After success-
ful isolation, the cells were cultivated in culture flasks to
remove the components of the extracellular matrix, and
their differentiated state was maintained in the presence
of chondrogenic differentiation stimulus TGF-β3 for 14
days, and 2 × 105 cells were transferred to chamber slides
for histologic and immunohistochemical assessment.
The chondrogenic potential of cultured cells showed a
positive expression of collagen type II (Figure 2A) com-
pared with control samples (Figure 2B). Similarly, the
chondrogenic-stimulated samples were positive for Alcian
blue staining (Figure 2C) compared with unstimulated
control samples (Figure 2D), indicating cartilage-specific
proteoglycan in the culture. This indicates that the cell-
isolation procedure, removal of extracellular matrix, and
subsequent cultivation does not affect the chondrogenic
potential of cultured cells.
Similarly, on the gene level, they showed significantly
higher expression of COL2A1 and SOX9 compared
with undifferentiated MSCs and unstimulated controls
(Figure 2E). After removing the extracellular compo-
nents, the cultured cells were isolated with trypsinization
(after 3 days) and subsequently analyzed for surface an-
tigens. The surface screening showed a reduced ex-
pression for CD44, CD73, CD90, CD105, and CD166
antigens (Figure 2F; see Additional file 3: Figure S2)
compared with undifferentiated MSCs (Figure 1H), indi-
cating that MSCs reduce their expression for above-
surface CD epitopes on chondrogenic differentiation.
This statement is further confirmed by the comparative
flow-cytometric analysis of surface antigens for three
independent donors, in chondrogenically differentiated
cells compared with undifferentiated and dedifferentia-
ted cells (see Additional file 2: Figure S5).
Figure 2 Isolation of chondrogenically differentiated cells and
their confirmation. Chondrogenically differentiated cells were
isolated from chondrogenic pellets. (A) Their chondrogenic
character showed a positive collagen type II, (C) and Alcian blue
staining, whereas the controls were negative for both (B) collagen
type II (D) and Alcian blue staining. (E) After 28 days of induction,
the chondrogenically differentiated cells showed significantly
upregulated expression for cartilage-specific genes like COL2A1 and
SOX9 compared with controls and undifferentiated cells, day 0
(n = 3), mean ± SEM. (F) Flow-cytometric analysis showed a relatively
lower expression of CD44, CD73, CD90, CD105, and CD166 antigens
compared with undifferentiated MSCs (n = 3). Student t test was
performed for statistical analysis, and asterisks were assigned in the
order P* < 0.05, P** < 0.01, and P*** < 0.001, mean ± SEM. Bar, 200 μm.
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To measure the chemotaxis potential for different states
of MSCs, the isolated chondrogenically differentiated
cells were dedifferentiated in the MSC culture/expansion
medium, to generate their dedifferentiated progeny.After five passages, they showed intensive proliferation
and converted into dedifferentiated progenitor cells. To
inspect whether the chondrogenic character is still
present in dedifferentiated cells, we examined them for
collagen type II expression. The collagen type II stai-
ning was almost as negative as that of control samples
(Figure 3A and B). Similar to control samples, they
showed negative Alcian blue staining (Figure 3C, D),
indicating the absence of proteoglycan in dedifferentia-
ted cells. On the gene level, they showed significantly
downregulated expression of COL2A1 and SOX9 genes
compared with chondrogenically differentiated cells
(Figure 3E). In conclusion, these results confirmed the
well-advanced state of dedifferentiation. Surface analysis
of CD antigens again showed higher expression for
CD44, CD73, CD90, CD105, and CD166 (Figure 3F; see
Additional file 4: Figure S3) compared with chon-
drogenic differentiated cells, but this is relatively lower
than MSC expression. Conclusively, the surface CD pro-
file of MSCs changed with differentiation, but was not
completely recovered after dedifferentiation, as con-
firmed by the quantitative measurement of surface anti-
gens of three independent donors (see Additional file 2:
Figure S5).
Migration of undifferentiated, chondrogenic
differentiated, and dedifferentiated cells in response to
serum-mediated chemotaxis
After generating different states of MSCs (undifferen-
tiated, chondrogenic differentiated, and their derived
dedifferentiated state), we performed the chemotaxis
assay to determine the relative effect of cell migration
on these states. As stem cells-guided migration is con-
sidered one crucial parameter among all preclinical
characterizing parameters [54,60]. Therefore, migration
potential was analyzed with 10% allogenic serum for un-
differentiated MSCs, chondrogenic differentiated, and
dedifferentiated cells. Undifferentiated MSCs showed in-
tensive hemacolor staining for migrated cells (Figure 4A)
compared with control samples (Figure 4B). The quanti-
fication-assessment tool of Image J software confirmed
the migration of about 3.3 × 104 cells for the undifferen-
tiated state of MSCs (Figure 4C). Similarly, the chon-
drogenically differentiated cells showed less hemacolor
staining for migrated cells (Figure 4D) compared with
the undifferentiated state of MSCs (Figure 4A). The con-
trol samples were negative (Figure 4E). The quantifica-
tion assessment confirmed the migration of about 1.3 ×
104 cells for the chondrogenic differentiated state of
MSCs (Figure 4F), suggesting that the differentiated state
limits the rate of cell migration. On subsequent dediffer-
entiation, the cells again showed higher hemacolor stain-
ing (Figure 4G) versus chondrogenic cells (Figure 4D) for
migrated cells. The control samples showed negligible cell
Figure 3 Dedifferentiation of chondrogenically differentiated
cells. Chondrogenically differentiated cells were converted to
dedifferentiated cells (A), which showed almost the same collagen
type II expression as (B) in control samples, and similarly (C) uniform
expression for Alcian blue staining, (D) like their unstimulated
control samples. (E) On the gene level, dedifferentiated cells showed
significantly downregulated expression of COL2A1 and SOX9 genes,
and confirmed the well-advanced state of dedifferentiation (n = 3).
(F) Flow-cytometric profile of CD markers showed a relatively lower
expression for dedifferentiated cells compared with the
undifferentiated state of MSCs (n = 3), Student ttest was performed
for statistical analysis, and asterisks were assigned in the order
P* < 0.05, P** < 0.01, and P*** < 0.001; mean ± SEM. Bar, 200 μm.
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sured the migration of about 3.4 × 104 cells for the
dedifferentiated state of MSCs (Figure 4I).
In conclusion, the percentage comparison relative to
total cell number (40 × 103) revealed about 33%, 84%,and 85% cell migration for the chondrogenic differen-
tiated, undifferentiated, and dedifferentiated states of
MSCs, respectively (Figure 4J). This is in line with the
statement that mature chondrocytes have relatively low
migration potential in vivo for cartilage repair, because
of its inherent architectural nature [20,22]. Allogenic
10% serum-mediated chemotaxis recruited relatively
more cells for the undifferentiated (84%) and dediffe-
rentiated states (85%), compared with the chondrogenic
differentiated state (33%) of MSCs.
Migration of undifferentiated, chondrogenic
differentiated, and dedifferentiated cells in response to
CCL25-mediated chemotaxis
Biochemically, the serum is a complex and an undefined
cue for diverse known and unknown functions, includ-
ing migration [39-42]. Hence, it emphasizes the need for
a known chemokine for guided and targeted cell migra-
tion. Moreover, CCL25 is an important chemoattractant
and well known to initiate the process of inflammation,
cellular mobilization, and migration of cells for effective
regeneration [63,64]. In this scenario, CCL25 has been
tested by our group [44,54] and reported as an import-
ant chemokine for targeted stem cell migration in regen-
erative medicine. Therefore, we assessed the relative
effect of cell migration on different states of MSCs
(undifferentiated, differentiated, and dedifferentiated),
by using different concentrations of CCL25 (500 nM,
750 nM, and 1,000 nM). At 1,000 nM concentration of
CCL25, we found almost uniform hemacolor staining for
undifferentiated (Figure 5A), chondrogenic differentia-
ted (Figure 5D), and dedifferentiated states of MSCs
(Figure 5G) compared with their respective controls
(Figure 5B, E, and H). The quantification assessment for
different states of MSCs was performed with Image J
software. For different concentrations of CCL25 (500 nM,
750 nM, and 1,000 nM), the quantitative analysis con-
firmed the differences in cell migration for different states
of MSCs. For instance, at 1,000 nM concentration, about
3.8 × 103 cells showed migration for the chondrogenic dif-
ferentiated state (Figure 5F), about 4.5 × 103 cells for the
undifferentiated state (Figure 5C), and about 4.4 × 103
cells for the dedifferentiated state (Figure 5I) of a total of
30 × 103 cells for each state of MSCs.
To show an obvious comparative representation of cell
migration in different states of MSCs, percentage quanti-
fication analysis was performed. The percentage quanti-
fication assessment with Image J software revealed a cell
migration of about 12% for the chondrogenic differenti-
ated state, about 14% for the undifferentiated state, and
about 13% for the dedifferentiated state of MSCs of a
total 30 × 103 cells (Figure 5J) in response to CCL25-
mediated chemotaxis at a concentration of 1,000 nM
chemokine.
Figure 4 Serum-mediated chemotaxis for undifferentiated, chondrogenic differentiated, and dedifferentiated states of MSCs. (A)
Serum-mediated chemotaxis showed higher hemacolor staining for MSCs compared with (B) control. (C) Quantification assessment with Image J
software revealed more migrated cells for undifferentiated MSCs compared with control. (D) Chondrogenically differentiated cells showed
intermediate hemacolor staining compared with (E) control, and (F) quantification assessment confirmed their low migration potential (33%). (G)
Similarly, dedifferentiated cells again showed intense hemacolor staining compared with (H) control, (I), and the number of migrated cells was
confirmed with Image J software. (J) The percentage of migrated cells relative to total cell number (40 × 103) is shown for undifferentiated,
chondrogenic differentiated, and dedifferentiated states of MSCs (n = 3). Student t test was performed for statistical analysis, and asterisks were
assigned in the order P* < 0.05, P** < 0.01, and P*** < 0.001, mean ± SEM. Bar, 200 μm.
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http://stemcellres.com/content/4/4/99In conclusion, chondrogenically differentiated cells
showed a low migration potential compared with undif-
ferentiated MSCs and dedifferentiated cells in response
to serum-mediated chemotaxis. The reason for this low
migration potential of chondrogenic differentiated cells
may be hidden in the loss/modification of migration-
specific receptors to serum, during differentiation. Con-
versely, chondrogenically differentiated cells had almost
equally migrated (12%) compared with undifferentiated
MSCs (14%) and dedifferentiated cells (13%) in response
to CCL25-mediated chemotaxis. This enhances the
value of CCL25 as a guided chemokine for cartilagerepair, as its chemotactic activity is not influenced by
the differentiated or undifferentiated nature of the
cells. Alternatively, the receptors taking part in the
CCL25-mediated chemotaxis, perhaps had not lost/
modified their expression, during chondrogenic diffe-
rentiation. However, CCL25 controls cellular traffic-
king irrespective of the cell architectural nature and
the differentiated state, so it is important to investi-
gate CCL25 as a migratory cue, in a broad spectrum,
as the concentration of CCL25 (1,000 nM) was main-
tained similarly for undifferentiated, differentiated, and
dedifferentiated states of MSCs.
Figure 5 CCL25-mediated chemotaxis for undifferentiated, chondrogenic differentiated, and dedifferentiated states of MSCs. (A) In
CCL25-mediated chemotaxis, the cell-migration assay showed almost uniform hemacolor staining for undifferentiated (D), chondrogenic
differentiated (G), and dedifferentiated states of MSCs compared with their (B, E, and H) respective controls. (F) Quantification assessment with
Image J software confirmed a relatively low level of migration for chondrogenically differentiated cells (12%) compared with (C) undifferentiated
and (I) dedifferentiated states of MSCs. (J) The percentage migration analysis relative to total cell number (30 × 103) is given for undifferentiated,
chondrogenic differentiated, and dedifferentiated states of MSCs (n = 3). Student t test was performed for statistical analysis, and asterisks were
assigned in the order P* < 0.05, P** < 0.01, and P*** < 0.001, mean ± SEM. Bar, 200 μm.
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almost equal rate of cell migration in CCL25-mediated
chemotaxis compared with undifferentiated and dediffe-
rentiated states of MSCs? CCR9, a binding receptor of
CCL25 chemokine, was investigated to determine the role
in guided cell migration.
Analysis of CCR9, a cellular receptor of CCL25 chemokine
CCL25 is an identified chemokine for stem cells-
targeted migration, and CCR9 is its known receptor
[54,57,58]. Thus, the undifferentiated, chondrogenic dif-
ferentiated, and dedifferentiated states of MSCs were ex-
amined for CCR9 expression. The undifferentiated stateof MSCs showed a bit greater and homogeneous staining
for CCR9 receptor (Figure 6A) compared with the chon-
drogenic differentiated (Figure 6D) and dedifferentiated
states (Figure 6G). The corresponding controls were
negative for all states of MSCs (Figures 6B, E, and H).
This indicates the presence of CCR9 receptor in only
undifferentiated, differentiated, and dedifferentiated states
of MSCs on a qualitative basis.
For quantitative measurement, flow-cytometric ana-
lysis was performed to examine the expression level of
CCR9 receptor. However, CCR9 receptor has two dis-
tinct domains called extracellular and intracellular; thus
flow-cytometric analysis was performed to screen all
Figure 6 Analysis of CCR9, a cellular receptor of CCL25 chemokine. The immunohistochemical analysis of CCR9 showed greater staining for
(A) the undifferentiated state compared with (D) chondrogenic differentiated and (G) dedifferentiated states of MSCs. The percentage flow-
cytometric measurement for extracellular and intracellular domains of CCR9 is given in the form of average (n = 3) with a horizontal line, and bars
represents a minimum or maximum expression for (C) undifferentiated state, (F) chondrogenic differentiated, and (I) dedifferentiated states of
MSCs. (J) On the gene level, the qPCR analysis revealed significantly upregulated expression for CCR9 receptor in the chondrogenic differentiated
state compared with undifferentiated and dedifferentiated states of MSCs (n = 3). Student t test was performed for statistical analysis, and asterisks
were assigned in the order P* < 0.05, P** < 0.01, and P*** < 0.001, average ± SD. Bar, 200 μm.
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http://stemcellres.com/content/4/4/99states of MSCs for its two domains. After analysis, their
expression was quantitatively expressed in the form of
averages, along with standard deviations (n = 3); here the
representative bars are divided to specify a minimum or
maximum expression. For undifferentiated (Figure 6C)
and chondrogenic differentiated (Figure 6F) states of
MSCs, the expression of extracellular and intracellular
domains was almost similar and about 10% for each do-
main, whereas for the dedifferentiated state of MSCs,
the expression of extracellular and intracellular domainswas about 18% and 5%, respectively (Figure 6I). The de-
tailed histogram plots for extracellular and intracellular
domains of CCR9 receptors are in the form of sup-
plemental files, for undifferentiated, chondrogenic differ-
entiated, and dedifferentiated states of MSCs (see
Additional file 5: Figure S4).
The expression level of CCR9 was almost homoge-
neous for extracellular (10%) and intracellular (10%)
domains, and collectively about 20% for each undifferen-
tiated and chondrogenic differentiated state of MSCs,
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state (Figure 6C, F, and I). On a molecular level, the
qPCR analysis was performed for CCR9 gene expression,
which showed significantly upregulated expression for
the chondrogenic differentiated state compared with
undifferentiated and dedifferentiated states of MSCs
(Figure 6J). Here, the protein and gene level expression
of CCR9 confirms the presence of receptor in undiffer-
entiated, differentiated, and dedifferentiated states of
MSCs.
Discussion
Guided stem cell migration is a vital approach for cell
recruitment to the point of injury or damage. For cartil-
age regeneration, the endogenous mobilization of chon-
drogenic cells and subsequent migration could be a
promising approach. In this context, the in vivo model
remains to be proven; however, we performed some pri-
mary experiments in vitro for guided cell migration of
chondrogenic differentiated cells, a step toward the
search for the right cells for the job. Cartilage tissue is a
combination of progenitor and differentiated cell types,
such as chondroblasts, chondrocytes, and dedifferen-
tiated cells [20,29,32]. Therefore, in the current study,
we analyzed the chemotactic ability of undifferentiated,
chondrogenic differentiated, and dedifferentiated states
of MSCs with serum- or CCL25-mediated chemotaxis.
Moreover, the surface profile of CD markers was investi-
gated to screen and specify the chondrogenic differen-
tiated state on the basis of typical MSC antigens. The
flow-cytometric analysis revealed a low level of expres-
sion for CD44, CD73, CD90, CD105, and CD166 anti-
gens in the chondrogenic differentiated state compared
with undifferentiated and dedifferentiated states of
MSCs, suggesting that chondrogenically differentiated
cells reduce their expression for these surface antigens.
In addition, these surface antigens are good characteriz-
ing markers for chondrogenically differentiated cells and
their progeny, and in line with previously published re-
ports, recommending the use of such surface markers
for identification of chondrogenic cells [65,66].
Chondrogenically differentiated cells were assessed
for cell migration in response to 10% allogenic serum-
mediated chemotaxis [39] or an established concentration
of 500 nM, 750 nM, and 1,000 nM CCL25-mediated
chemotaxis [44,54]. In serum-mediated chemotaxis, we
observed a significant decrease in recruited cells for the
chondrogenic differentiated state (33%) compared with
undifferentiated (84%) and dedifferentiated states (85%) of
MSCs. We would recommend the use of chondrogenically
differentiated cells for therapeutic repair of cartilage, as
they have active signaling pathways, chondrogenic charac-
ter, and biological paradigms of the differentiated state.
For fast-track regeneration, the cartilaginous nature andchemokinetic ability of chondrogenically differentiated
cells could be a beneficial asset.
For migration, serum is considered a very good che-
moattractant for recruitment of cells; however, its com-
position is very complex, and its role as yet unknown in
several biologic functions [40-42]. Therefore, we applied
CCL25 for cell recruitment, a well-known chemokine
for targeted stem cell migration [44,54]. Here, we no-
ticed negligibly low migration potential for chondroge-
nically differentiated cells compared with serum-mediated
chemotaxis.
In serum-mediated chemotaxis, we blame the inherent
architectural ability of the chondrogenic differentiated state
of MSCs for its limited cell migration. As chondrocytes
have limited mitotic potential, lack of innervations and vas-
cular supply, and are entrapped in the extracellular matrix,
almost no physical contact with each other and restricted
migration potential to the point of injury in vivo [20-22].
The CCL25-mediated chemotaxis has recruited 14%, 13%,
and 12% of cells, respectively for undifferentiated,
dedifferentiated, and chondrogenic differentiated states of
MSCs. Here, the migration rate of chondrogenically differ-
entiated cells was almost similar to the differentiated or
undifferentiated states of MSCs. Perhaps the activation of
some receptors and signaling in the chondrogenic differen-
tiated state is the cause of this higher chemotactic ability.
In this way, CCL25-mediated chemotaxis favors guided
cellular trafficking, and we recommend the use of CCL25
as a migratory cue in regenerative applications. This espe-
cially highlights the significant use of chondrogenically dif-
ferentiated cells for cartilage restoration because they have
almost the same migration potential compared with the
undifferentiated and dedifferentiated states of MSCs. The
collective use of CCL25 chemokine and chondrogenic dif-
ferentiated states of MSCs could be more beneficial for car-
tilage regeneration, possibly because of their active
signaling, so the use of chondrogenically differentiated cells
for cartilage repair could be fruitful.
We propose that chemotactic signals and inflamma-
tory response from injured sites could induce cellular
mobilization and create an intermediate pore sizes for
subsequent movement of cells to the injured sites. Our
suggestion is in line with the reports that inflammation
plays a critical role in the regeneration of cartilage tissue
[32,67-70].
Cytokine- and especially chemokine-based migration
is a crucial step for in vivo regenerative application
[43,71]. In this context, CCL25/CCR9 is a chemokine/re-
ceptor pair and plays a key regulative role in stem cell
migration [57,58]. In our study, the immunohistochemi-
cal analysis was performed for the assessment of CCR9
receptor, which showed almost uniform staining for un-
differentiated, differentiated, and dedifferentiated states
of MSCs, indicated the presence of receptors in these
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for immunohistochemical staining of CCR9 receptor,
which is a study limitation. For quantitative analysis,
flow-cytometric analysis was performed to measure the
expression of the extracellular and intracellular domains
of the CCR9 receptor. It has been reported that intracel-
lular signaling is required for CCL25 activation and
stimulation of chemoattractant ability [45,72]. The ex-
pression of extracellular and intracellular domains of
CCR9 collectively revealed about 20% expression for the
undifferentiated and chondrogenic differentiated states,
but about 23% expression for the dedifferentiated state
of MSCs.
On the molecular level, we analyzed all states of
MSCs for CCR9 gene expression by performing
qPCR, to identify the normalized amount of receptor
to GAPDH [73]. Gene analysis showed significantly
upregulated expression of CCR9 in the chondrogenic
differentiated state compared with the undifferentiated
and dedifferentiated states of MSCs. To correlate the
protein- and gene-level expression, we propose that
any apparent observational change in the protein and
gene level of the CCR9 receptor could be the cause
of posttranscriptional and posttranslational level
modification. In some cases, the protein-level expres-
sion of CCR9 does not correlate with mRNA level ex-
pression, and such noncorrelation of CCL25/CCR9
has been reported in mucosal immune systems on
protein and gene levels [57], and favors our specula-
tion about posttranslational modification. Further-
more, it also supports the Monte Carlo effect, a
hypothesis drawn about the biological importance that
the level of mRNA expression is not always directly
correlated with the protein expression [74]. In
addition, the chemotactic ability of CCL25 not only is
the result of a cellular receptor of CCR9, but also is
receiving signals from other receptors and signaling
cascades for activation, stimulation, and cellular mi-
gration [64].
The current study generated the knowledge of the
comparative surface CD profile, chemotaxis, and mig-
ration potential for undifferentiated, chondrogenic dif-
ferentiated, and dedifferentiated states of MSCs. To
understand the molecular mechanisms of migration in
different states of MSCs could be valuable to identify the
potential targets for wound healing, damage repair, and
regeneration.
Conclusions
The chemokines, cytokines, and growth factors in con-
sequence of inflammation facilitate cells homing to the
site of injury and improve tissue regeneration [75].
These regenerative strategies emphasize the importance
of targeted and guided chemotaxis for cell migration.Therefore, the chondrogenically differentiated cells were
investigated for their chemotactic ability. In this context,
chondrogenic pellets were generated from MSCs by
using chondrogenic differentiation medium for 28 days.
The chondrogenic nature of the pellets was confirmed
by proteoglycan-specific Alcian blue staining, cartilage-
specific collagen type II staining, and significantly
upregulated cartilage-specific genes COL2A1 and SOX9.
Then differentiated cells were isolated from the intact
chondrogenic pellets with enzymatic cues consisting of
300 U of collagenase II, 20 U of collagenase P, and
2 mM CaCl2 [59]. After successful isolation, the differen-
tiated cells were again verified for chondrogenic features,
and they were positive for Alcian blue staining, collagen
type II staining, and showed an upregulated expression
of COL2A1 and SOX9.
Afterward, the chondrogenically differentiated cells
were washed with PBS, and extracellular matrix was
removed; then their surface was analyzed for surface
CD antigens. The surface profile of chondrogenically
differentiated cells showed a positive expression of
CD44, CD73, CD90, CD105, and CD166, but notably
this expression was about 40% to 50% lower than that
in undifferentiated and dedifferentiated states of
MSCs. In serum-mediated chemotaxis, the number of
migrated cells was significantly lower for the
chondrogenic differentiated state (33%) compared
with the undifferentiated (84%) and dedifferentiated
(85%) states of MSCs, of a total 40 × 103 cells. In
CCL25-mediated chemotaxis, the number of migrated
cells was almost the same for the chondrogenic differ-
entiated state (12%) compared with undifferentiated
(14%) and dedifferentiated states (13%) of MSCs, of a
total of 30 × 103 cells.
The expression of CCR9 was examined with immu-
nohistochemistry and flow-cytometric analysis, which
confirmed the presence of CCR9 in undifferentiated, dif-
ferentiated, and dedifferentiated states of MSCs. On the
molecular level, the expression of CCR9 was significantly
upregulated in the chondrogenic differentiated state
compared with the undifferentiated and dedifferentiated
states of MSCs. We propose that CCL25-mediated
chemotaxis is influenced by the expression of CCR9 and
stimulates guided cell migration in all states of MSCs.
Cell migration as a result of mutual interaction of CCL25
and CCR9 has already been studied [57], and supports our
conclusive message of guided chemotaxis. Moreover, the
coupling interactions between CCL25 and CCR9 induce
cell migration in porcine mucosal tissue and in the im-
mune system during fetal development [57,58].
The in vivo migration of chondrogenically differentiated
cells remains to be proven; however, in vitro oriented cell
migration and homing study could provide valuable argu-
ments in this direction for further investigation.
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Additional file 1: Figure S1. Flow-cytometric analysis of
undifferentiated MSCs, isolated from bone marrow. MSCs in passage 3
(n = 3) were uniformly positive for typical surface markers like CD166,
CD105, CD90, CD73, and CD44, as examples given for a single donor, and
were negative for hematopoietic cell markers like CD45, CD34, and CD14.
Additional file 2: Figure S5. Comparative flow-cytometric profile of
undifferentiated, chondrogenic differentiated and dedifferentiated cells.
The comparative surface profile of CD markers showed a lower
expression for chondrogenically differentiated cells compared with
undifferentiated and dedifferentiated cells. Generally the undifferentiated,
differentiated, and dedifferentiated states of MSCs were positive for CD44,
CD73, CD90, CD105, and CD166 and negative for CD14, CD34, and CD45.
The Student t test was performed for statistical analysis, and asterisks
were assigned in the order P* < 0.05, P** < 0.01, and P*** < 0.001,
mean ± SEM. Red asterisks represent the statistical comparison of
undifferentiated cells versus dedifferentiated cells, whereas black asterisks
represent the statistical comparison of undifferentiated cells versus
chondrogenic differentiated cells.
Additional file 3: Figure S2. Flow-cytometric analysis of
chondrogenically differentiated cells, isolated from chondrogenic pellets.
Differentiated cells (n = 3) were positive for typical surface markers like
CD166, CD105, CD90, CD73, and CD44, as exemplary of a single donor,
and were negative for hematopoietic cell markers like CD45, CD34, and
CD14. However, their plot expressions were not uniform and showed
variations; moreover, chondrogenically differentiated cells significantly
reduced their expression (about 40% to 50%) for CD166, CD105, CD90,
CD73, and CD44.
Additional file 4: Figure S3. Flow-cytometric analysis of
dedifferentiated cells. After dedifferentiation, the cells (n = 3) again
showed higher expression for typical surface markers like CD166, CD105,
CD90, CD73, and CD44, as examples of a single donor, and were
negative for hematopoietic cell markers like CD45, CD34, and CD14.
However, their plot expressions were not uniform and showed variations;
moreover, dedifferentiated cells significantly recovered their expression
compared with chondrogenically differentiated cells but still were
relatively lower than undifferentiated MSCs.
Additional file 5: Figure S4. Flow-cytometric analysis of CCR9 receptor.
Undifferentiated, chondrogenic differentiated and dedifferentiated cells
(n = 3) were analyzed for CCR9, which is a cognate receptor of CCL25
chemokine. For complete assessment, the CCR9 examination was divided
into extracellular and intracellular analysis, as examples of a single donor,
which showed relatively lower level of expression for undifferentiated
MSCs compared with chondrogenic differentiated and dedifferentiated
cells. Moreover, the expression-profile plots, especially for the intracellular
domain, were flatter compared with the extracellular domains.Abbreviations
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